Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 2 March, 10am to 5pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:
1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Miriam McCarthy (proxy Vice Chair) Present for all notes
3. Dr Jeff Aronson Present for all notes
4. Professor John Cairns Present for all notes
5. Mr Mark Chapman Present for all notes
6. Dr Mark Glover Present for all notes
7. Dr Rebecca Kearney Present for all notes
8. Dr Sanjay Kinra Present for all notes
9. Mr Christopher O'Regan Present for all notes
10. Professor Stephen Palmer Present for all notes
11. Professor John Pounsford Present for all notes
12. Mr Alun Roebuck Present for all notes
13. Dr Nigel De-Kare Silver Present for notes 1 to 18
14. Dr Marta Soares Present for all notes
15. Dr Nicky Welton Present for all notes
16. Mr Nigel Westwood Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes

Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Helen Tucker Technical Analyst, National Institute for Health and Care Excellence Present for notes 1 to 18

Raisa Sidhu Technical Adviser, Present for notes 1 to 18
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Victoria Kelly</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>19 to 33</td>
</tr>
<tr>
<td>Dr Rosie Lovett</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>19 to 3</td>
</tr>
<tr>
<td>Professor Matt Stevenson</td>
<td>Technical Director, School of Health and Related Research</td>
<td>1 to 16 and for notes 19 to 29</td>
</tr>
<tr>
<td>Dr Inigo Bermejo</td>
<td>Research Associate, School of Health and Related Research</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Dr Katy Cooper</td>
<td>Senior Research Associate, School of Health and Related Research</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Dr Shuaib Nasser</td>
<td>Clinical expert, Consultant Physician in Allergy &amp; Asthma, Cambridge University Hospitals NHS Foundation Trust, nominated by the British Society of Allergy and Clinical Immunology (BSACI)</td>
<td>1 to 14</td>
</tr>
<tr>
<td>Professor Andrew Wardlaw</td>
<td>Clinical expert, Professor of Allergy and Respiratory Medicine, University of Leicester and University Hospitals of Leicester, nominated by the RCP</td>
<td>1 to 14</td>
</tr>
<tr>
<td>Lehanne Sergison</td>
<td>Patient expert, nominated by Asthma UK</td>
<td>1 to 14</td>
</tr>
</tbody>
</table>

**Non-public observers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Grainger</td>
<td>Senior Medical Editor, NICE</td>
<td>All notes</td>
</tr>
<tr>
<td>Cathryn Hall</td>
<td>Project Manager, NICE</td>
<td>All notes</td>
</tr>
<tr>
<td>Chloe Kastoryano</td>
<td>Public Involvement Adviser, NICE</td>
<td>1 to 18</td>
</tr>
<tr>
<td>Edgar Masanga</td>
<td>Business Analyst - Resource Impact Assessment, NICE</td>
<td>1 to 18</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of mepolizumab for treating severe eosinophilic asthma and cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).

2. The Chair welcomed Dr Mark Glover to his first meeting as a member of the Appraisal Committee.

3. The Chair informed the Committee of the non-public observers at this meeting: Linda Grainger, Chloe Kastoryano and Edgar Masanga.

4. Apologies were received from Dr Ray Armstrong, Dr Neil Iosson, Professor Ruairidh Milne, Dr Sanjeev Patel, Dr Danielle Preedy and Professor Ken Stein.

Any other Business

5. The Committee were given an update on developments relating to the Cancer Drugs Fund.

Appraisal of mepolizumab for treating severe eosinophilic asthma [ID798]

Part 1 – Open session

6. The Chair welcomed the invited experts: Professor Matt Stevenson, Dr Inigo Bermejo, Dr Katy Cooper, Dr Shuaib Nasser, Professor Andrew Wardlaw and Lehanne Sergison to the meeting and they introduced themselves to the Committee.

7. The Chair welcomed company representatives from GlaxoSmithKline to the meeting.

8. The Chair asked all Committee members to declare any relevant interests

8.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O’Regan, Professor Stephen Palmer, Professor John Pounsford, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

9. The Chair asked all NICE Staff to declare any relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the
technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

10.1. Professor Matt Stevenson, Dr Inigo Bermejo, Dr Katy Cooper and Lehanne Sergison declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

10.2. Dr Shuaib Nasser declared a personal specific financial interest as he has received financial support from GlaxoSmithKline.
10.2.1. It was agreed that this declaration would not prevent Dr Nasser from participating in this section of the meeting

10.3. Professor Andrew Wardlaw declared a personal specific financial interest as he has received financial support for research and has attended advisory boards for GlaxoSmithKline (though not related to mepolizumab) and other pharmaceutical companies.
10.3.1. It was agreed that this declaration would not prevent Professor Wardlaw from participating in this section of the meeting

11. The Chair introduced the lead team, Dr John Pounsford, Dr Marta Soares and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of mepolizumab for treating severe eosinophilic asthma.

12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.

16. The Evidence Review Group representatives left the meeting.

17. The committee decision was based on consensus.

18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
Appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255) [ID889]

Part 1 – Open session

19. The Chair welcomed the invited experts: Professor Matt Stevenson to the meeting and they introduced themselves to the Committee.

20. The Chair welcomed company representatives from Sanofi to the meeting.

21. The Chair asked all Committee members to declare any relevant interests

21.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Pounsford, Mr Alun Roebuck, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).

22. The Chair asked all NICE Staff to declare any relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).

23. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

23.1. Professor Matt Stevenson declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).

24. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be
prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

27. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

28. Discussion on confidential information continued. This information was supplied by the company.

29. The Evidence Review Group representative left the meeting.

30. The Committee continued to discuss the clinical and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).

31. The committee decision was based on consensus.

32. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

33. Wednesday 6 April 2016 at 10 Spring Gardens, London SW1A 2BU